Latest Articles
Increases in the susceptibility of human endometrial CD4 + T cells to HIV-1 infection postmenopause are not dependent on greater viral receptor expression frequency - Frontiers
Increases in the susceptibility of human endometrial CD4 + T cells to HIV-1 infection postmenopause are not dependent on greater viral receptor expression frequency Frontiers
Published: Dec. 26, 2024, 11:06 a.m.
Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment - Frontiers
Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment Frontiers
Published: Dec. 24, 2024, 7:10 p.m.
Research Bolsters Need for Enhanced Surveillance After Radiotherapy for Endometrial Cancer - Oncology Nurse Advisor
Research Bolsters Need for Enhanced Surveillance After Radiotherapy for Endometrial Cancer Oncology Nurse Advisor
Published: Dec. 23, 2024, 5 p.m.
QOL With Shorter RT Equal to Standard in Endometrial Cancer - Medscape
QOL With Shorter RT Equal to Standard in Endometrial Cancer Medscape
Published: Dec. 23, 2024, 1:27 p.m.
Deep learning for endometrial cancer subtyping and predicting tumor mutational burden from histopathological slides - Nature.com
Deep learning for endometrial cancer subtyping and predicting tumor mutational burden from histopathological slides Nature.com
Published: Dec. 21, 2024, 9:20 a.m.
HLA-DMB Correlates With Antitumor Immunity and an Improved Prognosis in Endometrial Carcinoma Tumors - Frontiers
HLA-DMB Correlates With Antitumor Immunity and an Improved Prognosis in Endometrial Carcinoma Tumors Frontiers
Published: Dec. 20, 2024, 4:13 p.m.
CCNA2 deficiency impairs endometrial responsiveness to steroids - BioWorld Online
CCNA2 deficiency impairs endometrial responsiveness to steroids BioWorld Online
Published: Dec. 20, 2024, 2 p.m.
Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer - Nature.com
Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer Nature.com
Published: Dec. 20, 2024, 10:34 a.m.
Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer - OncLive
Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer OncLive
Published: Dec. 19, 2024, 4:30 p.m.
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors - Medpage Today
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors Medpage Today
Published: Dec. 18, 2024, 8:16 p.m.
Link copied to clipboard!